RYSTIGGO is a drug for the treatment of generalized myasthenia gravis (gMG) in adult patients. It is used by patients whose blood has antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK).
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rystiggo
No hay comentarios:
Publicar un comentario